Cellectis S.A. American Depositary Shares

CLLS XNAS

Historical Short Interest Share

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Market Cap

340M

Short interest (May 15)

0.3%

Net Short (Jun 03 ): 0.0%

Borrow Fee

0.52%

↑ 77.7%

Available Shares

900K

↓ 8.5%

Price Chart

Company Overview

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Company Info

Exchange: NASDAQ

CIK: 0001627281

Asset Type: ADRC

Market Data

Market Cap: $340,066,805

Employees: 229

Status: Active

Short Interest

Current Borrow Fee 0.52%

Range: 0.52% - 0.53%

Available Shares 900K

Range: 800K - 900K

Recent Changes

Fee Change: ↓ 21.3%

Available Change: ↓ 0.0%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime